Pharmacokinetics of sulbactam/ampicillin in humans: A review

Reviews of Infectious Diseases

Volumn 8, Issue , 1986, Pages 8-511

  Foulds, George ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; BETA LACTAMASE; BETA LACTAMASES; PENICILLANIC ACID; SULBACTAM; SULTAMICILLIN;

DRUG COMBINATION; FEMALE; HALF LIFE TIME; HUMAN; KINETICS; MALE; METABOLISM; NEWBORN; PREGNANCY; REVIEW; TISSUE DISTRIBUTION;

AMPICILLIN; BETA-LACTAMASES; DRUG COMBINATIONS; FEMALE; HALF-LIFE; HUMAN; INFANT, NEWBORN; KINETICS; MALE; PENICILLANIC ACID; PREGNANCY; SULBACTAM; TISSUE DISTRIBUTION;

EID: 84960614013     PISSN: 01620886     EISSN: None     Source Type: Journal    
DOI: 10.1093/clinids/8.Supplement_5.503     Document Type: Article

References (49)

1. Brenner DG, Knowles JR, Rihs G. Penicillin acid sulfone: an unexpected isotope effect in the interaction of 6a- and 6P-monodeuterio and of 6,6-dideuterio derivatives with RTEM 3-lactamase from Escherichia coli. Biochemistry 1981;20:3680-7
2. English AR, Retsema JA, Girard AE, Lynch JE. Barth WE. CP-45,899, a beta-lactamase inhibitor that extends the antibacterial spectrum of beta-lactams: initial bacteriological characterization. Antimicrob Agents Chemother 1978;14:414-9
3. Kemal C, Knowles JR. Penicillanic acid sulfone: interaction with RTEM p-lactamase from Escherichia coli at different pH values. Biochemistry 1982;20:3688-95
4. Labia R, Lelievre V, Peduzzi J. Inhibition kinetics of three R-factor-mediated P-lactamases by a new P-lactam sulfone (CP-45,899). Biochim Biophys Acta 1980;611:351-7
5. Retsema JA, Schelky WU, Girard AE, English AR. Beta- lactamase inhibitor CP-45,899 (sulbactam) mode of action against a type III beta-lactamase and synergy effects with cephalosporins. Drugs Under Experimental and Clinical Research 1981;7:255-61
6. Aswapokee N, Neu HC. A sulfone P-lactam compound which acts as a P-lactamase inhibitor. J Antibiot (Tokyo) 1978;31: 1238-44
7. Fu KP, Neu HC. Comparative inhibition of P-lactamases by novel P-lactam compounds. Antimicrob Agents Chemother 1979;15:171-6
8. Retsema JA, English AR, Girard AE. CP-45, 899 in combination with penicillin or ampicillin against penicillin- resistant Staphylococcus, Haemophilus, and Bacteroides. Antimicrob Agents Chemother 1980;17:615-22
9. Wise R, Andrews JM, Bedford KA. Clavulanic acid and CP- 45,899: a comparison of their in vitro activity in combination with penicillins. J Antimicrob Chemother 1980;6: 197-206
10. Foulds G, Barth WE, Bianchine JR, English AR, Girard D, Hayes SL, O’Brien MM, Somani P. Pharmacokinetics of CP-45,899 and pro-drug CP-47,904 in animals and humans. In: Nelson, JD, Grassi C, eds. Current chemotherapy and infectious disease. Washington, DC: American Society for Microbiology, 1980:353.
11. Baltzer B, Binderup E, von Daehne W, Godtfredsen WO, Hansen K, Nielsen B, Sorensen H, Vangedal S. Mutual prodrugs of P-lactam antibiotics and P-lactamase inhibitors. J Antibiot (Tokyo) 1980;33:1183-92
12. Foulds G, Stankewich JP, Marshall DC, O’Brien MM, Hayes SL, Weidler DJ, McMahon FG. Pharmacokinetics of sulbactam in humans. Antimicrob Agents Chemother 1983;23:692-9
13. Van Der Auwera P, Klastersky J. Serum bactericidal activity of ampicillin and mezlocillin with and without sulbactam. Drugs Under Experimental and Clinical Research 1984; 10:333-43
14. Foulds G, Knirsch AK, Stankewich JP, Weidler DJ. The parenteral kinetics of ampicillin/sulbactam in man. Clinical Pharmacology Research 1985;5:79-86
15. Brown RN, Wise R, Andrews JM, Hancox J. Comparative pharamacokinetics and tissue penetration of sulbactam and ampicillin after concurrent intravenous administration. Antimicrob Agents Chemother 1982;21:565-67
16. Rogers HJ, Bradbrook ID, Morrison PJ, Spector RG, Cox DA, Lees LJ. Pharmacokinetics and bioavailabilty of sul- tamicillin estimated by high performance liquid chromatography. Antimicrobial Agents Chemother 1983;11:435-45
17. Caine VA, Foulds G, Handsfield HH. Therapeutic trial and pharmacokinetics of sulbactam for uncomplicated gonorrhea in men. Antimicrob Agents Chemother 1984;26:683-5
18. Morris DL, Ubhi CS, Robertson CS, Brammer KW. Biliary pharmacokinetics of sulbactam plus ampicillin in humans. Rev Infect Dis 1986;8(Suppl 5):S589-92
19. Kager L, Liljeqvist L, Malmborg A-S, Nord C-E, Pieper R. Effects of ampicillin plus sulbactam on bowel flora in patients undergoing colorectal surgery. Antimicrob Agents Chemother 1982;22:208-12
20. Boelaert J, Robbens E, Daneels R, Schurgers M, Lambert AM, Van Landuyt HW. Pharmacokinetics of sulbactam and ampicillin in patients with renal impairment after a single oral dose of sultamicillin [abstract no. 842] In: Program and abstracts of the 23rd Interscience Conference on Antimicrobial Agent and chemotherapy. Washington, DC: American Society for Microbiology, 1983
21. Wright N, Wise R. The elimination of sulbactam alone and combined with ampicillin in patients with renal dysfunction. J Antimicrob Chemother 1983;11:583-7
22. Jusko WJ, Lewis GP, Schmitt GW. Ampicillin and hetacillin pharmacokinetics in normal and anephric subjects. Clin Pharmacol Ther 1973;14:90-9
23. Philipson A. Pharmacokinetics of ampicillin during pregnancy. J Infect Dis 1977;136:370-6
24. Foulds G, Miller RD, Stankewich JP, Knirsch AK, Thrupp L. The pharmacokinetics of sulbactam and ampicillin in post-partum women. In: Spitzy KH, Karrer K, eds. Proceedings of the 13th International Congress of Chemotherapy. Vol 1. Vienna: Verlag H Egermann, 1983:23 17
25. Foulds G, Miller RD, Knirsch AK, Thrupp LD. Sulbactam kinetics and excretion into breast milk in post-partum women. Clin Pharmacol Ther 1985;38:692-6
26. Dubois M, Coibion M, Deco J, Delapierre D, Lambotte R, Dresse A. The transplacental transfer of sulbactam sodium when co-administered with ampicillin to healthy pregnant women in labor. In: Spitzy KH, Karrer K, eds. Proceedings of the 13th Congress of Chemotherapy. Vol 1. Vienna: Verlag H Egermann, 1983:23/23
27. Sutton AM, Turner TL, Cockburn F, McAllister TA. Pharmacokinetic study of sulbactam and ampicillin administered concomitantly by intraarterial or intravenous infusion in the newborn. Rev Infect Dis 1986;8(Suppl 5):S518-22
28. Yoshioka H, Takimoto M, Riley HD Jr. Pharmacokinetics of ampicillin in the newborn Infant. J Infect Dis 1974;129:461-4
29. McCracken GH Jr, Nelson JD. Antimicrobial therapy for newborns: practical application of pharmacology to clinical usage. New York: Grune & Stratton, 1977:5-68
30. Schaad UB, Guenin K, Straethl P. Single-dose pharmacokinetics of intravenous sulbactam in pediatric patients. Rev Infect Dis 1986;8(Suppl 5):S512-7
31. Gill MA, Kern JW, Chenella FC, Heseltine PNR, Yellin AE, Foulds G, Berne TV. Pharmacokinetics of parenteral sulbactam in patients with appendicitis. Ther Drug Monit 1984;6:428-31
32. Triggs EJ, Johnson JM, Learoyd B. Absorption and disposition of ampicillin in the elderly. Eur J Clin Pharmacol 1980;18:195-8
33. Klotz U. Pathophysiological and disease-induced changes in drug distribution volume: pharamacokinetic implications. In: Gibaldi M, Prescott L, eds. Handbook of clinical phar-macokinetics. Section III. New York: ADIS Health Science Press, 1983:41-56
34. Benet LZ, Galeazzi RL. Noncompartmental determination of the steady-state volume of distribution. J Pharm Sci 1978;68:1071-4
35. Perrier D, Mayersohn M. Noncompartmental determination of the steady-state volume of distribution for any mode of administration [letter]. J Pharm Sci 1982;71:372-3
36. Mims CA. The pathogenesis of infectious disease. 2nd ed. New York: Academic Press, 1982:53
37. Hoffstedt B, Walder M, Haidl S. Distribution of sulbactam and ampicillin into subcutaneous tissue fluid obtained by implanted cotton threads or by suction blisters in human volunteers. In: Program and abstracts of the 6th International Symposium on Future Trends in Chemotherapy, Pisa, Italy, 1984
38. Wise R, Donovan IA, Andrews JM, Drumm J, Bennett S, Penetration of sulbactam and ampicillin into peritoneal fluid. Antimicrob Agents Chemother 1983;24:290-2
39. Houang ET, Chapman M, Dewhurst J. The prophylactic use of sulbactam and ampicillin in major gynecological surgery. In: Spitzy KH, Karrer K, eds. Proceedings of the 13th International Congress of Chemotherapy. Vol 1. Vienna: Verlag H Egermann, 1983;23-29
40. Houang ET, Colley N, Chapman M. Penetration of sulbactam-ampicillin and clavulanic acid-amoxicillin into the pelvic peritoneum. Antimicrob Agents Chemother 1985;28:165-6
41. Foster MC, Kapila L, Morris DL, Slack RCB. A randomized comparative study of sulbactam plus ampicillin vs. metronidazole plus cefotaxime in the management of acute appendicitis in children. Rev Infect Dis 1986;8(Suppl 5):S634-8
42. Sanders CV, Marier RL. Penetration of sulbactam into human cerebrospinal Fluid. In: Spitzy KH, Karrer K, eds. Proceedings of the 13th International Congress of Chemotherapy. Vol 1. Vienna: Verlag H Egermann, 1983:23-31
43. Stahl JP, Bru J-P, Fredj G, Brammer KW, Mallaret M-R, Micoud M. Penetration of sulbactam into the cerebrospinal fluid of patients with bacterial meningitis receiving ampicillin therapy. Rev Infect Dis 1986;8(Suppl 5):S612-6
44. Hanninen P, Rossi T. Penetration of sulbactam into cerebrospinal fluid of patients with viral meningitis or without meningitis. Rev Infect Dis 1986;8(Suppl 5):S609-11
45. Rodriguez WJ, Kahn W, Puig J, Feris J, Harmon S, Gold BG, Ahmad S. Sulbactam/ampicillin vs. chlorampheni- col/ampicillin for the treatment of meningitis in infants and children. Rev Infect Dis 1986;8(Suppl 5):S620-9
46. Dorflinger T, Madsen PO. Antibiotic prophylaxis in transurethral surgery: a comparison of sulbactam-ampicillin and cefoxitin. Infection 1985;13:66-9
47. Maesen FPV, Davies BI, van Noord JA, Teengs JP. An open non-comparative study to assess the pharmacokinetics, efficacy and safety of a combination of sulbactam sodium with ampicillin in the treatment of acute exacerbations of chronic bronchitis. In: Spitzy KH, Karrer K, eds. Proceedings of the 13th International Congress of Chemotherapy. Vol 3. Vienna: Verlag H Egermann, 1983:55-82
48. Davies BI, Maesen FP, van Noord JA. Clinical, bacteriological and pharmacokinetic results from an open trial of sul- tamicillin in patients with acute exacerbations of chronic bronchitis. J Antimicrob Chemother 1984;13:161-70
49. Reilly JS, Kim HK, Rohn DD. Concentrations of sultamicil- lin in serum and middle ear fluid of children with chronic otitis media with effusion. Ann Otol Rhinol Laryngol 1983;92(Suppl 107):44-5